News & Media
Press Releases
Amolyt Pharma Announces Abstracts Accepted for Presentation at ECE and ENDO
May 16, 2022
Download a PDF copy of this press release: EN FR LYON, France, and Cambridge, MA, May 16, 2022 — Amolyt Pharma, a global company specialized …
Amolyt Pharma Announces US IND Clearance for the Ongoing Clinical Trial of AZP-3601 in Patients with Hypoparathyroidism
March 17, 2022
Download a PDF copy of this press release: EN FR Top-line safety and efficacy data from ongoing clinical trial in patients with hypoparathyroidism expected mid-2022 …
Amolyt Pharma Announces European Commission Has Granted Orphan Drug Designation to AZP-3601 for the Treatment of Hypoparathyroidism
March 1, 2022
Download a PDF copy of this press release: EN FR Top-line data from ongoing clinical trial in patients with hypoparathyroidism expected mid-2022 LYON, France, and …
Presentations
- All PRESENTATIONS
- AZP-3813
- AZP-3601
All PRESENTATIONS
- All PRESENTATIONS
- AZP-3813
- AZP-3601
AZP-3601
Healthcare Resource Utilization Burden of Patients with Hypoparathyroidism in the United States
Written by
walid
Upcoming events
Hypopara Awareness Day
Date: June 1, 2022
ENDO 2022 – Annual Meeting of the Endocrine Society
Date: June 10 – June 14, 2022 (Atlanta, Georgia)
ASBMR 2022 Annual Meeting
Date: September 9 - 12, 2022 (Austin, TX)
Social Updates
TWITTER
Earlier this week, we announced that we will be presenting at the 2022 @ESEndocrinology conference, ...
Read More »RT @LifeSciAdvisors: Tune into Episode 37 of the Benchtop Bios Podcast Series, featuring Dr. Thierry...
Read More »Check out this video featuring Soraya Allas, MD, Ph.D., our VP of clinical development and regulator...
Read More »